I HUB's Rob, made a very striking comment regarding George Soros, substantially improving a recent biotech investment decision, Plasma Tech (PTBI:NASDAQ). The great thing about Rob's comment is that the biotech compound Brilacidin OM, which Rob believes will prove his bold exclamation, is about to enter FDA stage 2 trials. The data from these trials should ring the bell loudly in favor of Rob's thesis, or be an amplifier for taps to be played with regards to his clairvoyance. I expect the bell to ring loudly in favor of Rob's clairvoyance. Whatever, we are now in a time event trajectory to prove up Rob's position.
|Rob_||Wednesday, 05/27/15 03:48:59 PM|
|Re: To infinity and beyond! post# 104660|
|Post # of 104753|
Oral mucositis is becoming known as an important medical problem. George Soros recently (5/4/15) took a big position in PlasmaTech Biopharmaceuticals, Inc. (PTBI) (see Yahoo Finance Profile below) which markets MuGard for oral mucositis and ProctiGard for radiation proctitis. Check its chart for May. In my opinion, he took an interest in the wrong company. Brilacidin-OM has more potential. MuGard is not so much a drug as just a mix of common ingredients.
MuGard Ingredients: Purified water, glycerin, benzyl alcohol,
sodium saccharin, Carbomer Homopolymer A,
potassium hydroxide, citric acid, polysorbate 60 and
Ella Ruth insertion, (now read about Brilacidin Oral Mucositis).
Brilacidin-OM can possibly be used for radiation proctitis (notice the similarity with ulcerative proctitis - it does exist! - see Ulcerative proctitis).
Many uses for Brilacidin - OM in the future: oral mucositis, radiation proctitis, ulcerative proctitis, ?ulcerative colitis, ?Crohn's disease
PlasmaTech Biopharmaceuticals, Inc. operates as a biopharmaceutical company and develops protein biologic therapies and oncology supportive care products. The company?s marketed product comprises MuGard the management of oral mucositis; and ProctiGard for the treatment of radiation proctitis, a frequent side effect of radiation treatment to the pelvic region. It also develops CobOral, a mediated oral delivery technology that utilizes the body?s natural vitamin B12 transport system in the gut; and CobaCyte, a mediated targeted delivery technology that has application in in tumor targeting. The company was formerly known as Access Pharmaceuticals Inc. and changed its name to PlasmaTech Biopharmaceuticals, Inc. in October 2014. The company was incorporated in 1989 and is based in Dallas, Texas.
Remember its not if, its just when or how soon that Rob will be right or otherwise. I would anticipate that over the next 12 months that Cellceutix shares will attract some most noteworthy investors. The scientific progress made to date and slated to follow should be compelling.
Disclosure: The author is long 10,000 SHARES OF CTIX.